Lyon, April 15, 2020 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, publishes the total number of shares and voting rights forming its share capital ( In accordance with Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) as of March 31, 2020.
Date | Total of outstanding shares | Theoretical voting rights |
March 31, 2020 | 3 622 413 | 4 920 863 |
|
Contacts THERANEXUS Thierry Lambert Financial and Administrative Director investisseurs@theranexus.fr FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr | ACTUS finance & communication Caroline Lesage Investor Relations +33 (0)1 53 67 36 79 theranexus@actus.fr |
- SECURITY MASTER Key: yWdslMicYprJnptsaplubGiXmmyVxWWYaWfGx2NxYpucaGqVlGpnbZWYZm9jnmxs
- Check this key: https://www.security-master-key.com.
https://www.actusnews.com/documents_communiques/ACTUS-0-62976-theranexus_pr_ddv_31032020.pdf
© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free